iRadimed Corp (IRMD) Reports Record Revenues and Robust Earnings Growth in Q4 and Full-Year 2023
-
Revenue Growth: Q4 revenue increased by 17.4% year-over-year, with full-year revenue up by 23.1%.
-
Net Income: Q4 net income rose to $4.5 million, with a full-year net income of $17.2 million, marking significant increases from the previous year.
-
Earnings Per Share (EPS): GAAP diluted EPS for Q4 was $0.36, and $1.35 for the full year, showing a notable rise from 2022.
-
Non-GAAP Adjustments: Non-GAAP net income for Q4 was $5.0 million, and $18.9 million for the full year, excluding stock-based compensation expense.
-
Cash Flow: Operating cash flow for the year was $13.5 million, with a free cash flow of $5.5 million after significant capital expenditures.
-
Guidance for 2024: iRadimed Corp projects revenue between $72.0 million and $74.0 million and GAAP diluted EPS between $1.37 and $1.47 for the full year.
On February 8, 2024, iRadimed Corp (NASDAQ:IRMD) released its 8-K filing, announcing financial results for the fourth quarter and full year of 2023. The company, known for its innovative MRI-compatible medical devices, reported a year of record revenues and substantial earnings growth.
Company Overview
iRadimed Corp develops, manufactures, and distributes MRI-compatible IV infusion pump systems and patient vital signs monitoring systems, along with related accessories and services. These products are designed to be safe for use during MRI procedures and are sold primarily to hospitals and acute care facilities both in the U.S. and internationally.
Financial Performance and Challenges
The company's performance in the fourth quarter was marked by a 17.4% increase in revenue year-over-year, reaching $17.5 million. This growth was driven by robust sales in both the IV infusion pump product line and the monitoring business. Net income for the quarter also increased to $4.5 million, or $0.36 per diluted share, up from $3.7 million, or $0.29 per diluted share in the fourth quarter of 2022.
For the full year, iRadimed reported a revenue of $65.6 million, a 23.1% increase from the previous year. The net income for the year was $17.2 million, or $1.35 per diluted share, compared to $12.8 million, or $1.02 per diluted share for 2022. These financial achievements underscore the company's ability to grow its market share and maintain profitability in the competitive Medical Devices & Instruments industry.
Despite these strong results, the company faces challenges, including the need to continuously innovate and address the competitive pressures within the medical device sector. Additionally, the company anticipates a cash outlay of approximately $13 million towards the development of a new facility in Orlando, FL, which could impact short-term cash flows.